Alkermes Plc (ALKS) Stock Price, Quote & News

Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed product...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 353 1 772 8000

Website: www.alkermes.com

Address:

Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland

Otus Feb. 21 at 10:42 PM

$ALKS if b of a Analysis gives this a neutral rating and given their history with avadel and jazz, then this is more than likely a strong buy with a price target of 42 plus.

0 · Reply

erevnon Feb. 20 at 11:48 AM

B of A Securities maintains Alkermes $ALKS at Neutral and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

SuperGreenToday Feb. 19 at 12:13 PM

$ALKS Share Price: $32.02 Contract Selected: May 15, 2026 $30 Calls Buy Zone: $4.59 – $5.67 Target Zone: $8.17 – $9.98 Potential Upside: 68% ROI Time to Expiration: 84 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

$NVO's Wegovy gets EC nod for higher dose — but is it enough to boost the stock? NVO shares down 9.9% in six months, lagging the industry’s 27.4% growth New 7.2 mg Wegovy dose shows promising weight loss results, yet the stock carries a Zacks Rank #5 (Strong Sell) Some better-ranked stocks are $HRMY, $ALKS, and $CSTL. Opportunity or risk? Full analysis here 👉 https://www.zacks.com/stock/news/2871232/eu-approves-novo-nordisks-higher-dose-wegovy-for-obesity-patients?cid=sm-stocktwits-2-2871232-body-33960&ADID=SYND_STOCKTWITS_TWEET_2_2871232_BODY_33960

0 · Reply

Otus Feb. 17 at 5:08 PM

$ALKS bought several thousand more shares today.

1 · Reply

OfficialStocktwitsUser Feb. 16 at 2:07 PM

$ALKS RSI: 50.29, MACD: 0.9256 Vol: 0.96, MA20: 33.85, MA50: 30.85 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Its_Only_Money_369 Feb. 13 at 11:04 PM

$ALKS $AVDL Can anyone explain why my June and January AVDL options that were OTM have been converted to 2/20/26 Options? I had 17.50 and 20.00 puts and 22.50 calls. They are not tradable but appear as if they can still be exercised. I sold all my 20.00 calls thinking I would loose the positive spread on the buyout. Now I’m questioning if I could have held them and exercised them with cash from shares and recieved 100 CVRs for each contract🧐

0 · Reply

LarryYMB Feb. 13 at 3:07 PM

$AVDL asta la vista, it didn't work fully as expected, will see you at $ALKS , cheers to you all winners, and before I forget, fk you anphony!

2 · Reply

Otus Feb. 12 at 5:07 PM

$ALKS added a few thousand shares today.

0 · Reply

jim22u Feb. 12 at 4:53 PM

$ALKS Back in for 1500 shares. Buying the fear.

0 · Reply

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

AVDL

Feb 11, 2026, 4:00 PM EST - 11 days ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

Jan 13, 2026, 4:25 PM EST - 5 weeks ago

Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 9:16 PM EST - 6 weeks ago

Alkermes: Avadel Deal And Vibrance-2 Unlock Upside

Jan 6, 2026, 7:00 AM EST - 6 weeks ago

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

Dec 30, 2025, 4:00 PM EST - 7 weeks ago

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 4:38 PM EST - 2 months ago

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

Dec 5, 2025, 7:08 PM EST - 2 months ago

Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 25, 2025, 4:00 PM EST - 3 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 19, 2025, 6:08 AM EST - 3 months ago

Alkermes raises offer for Avadel after Lundbeck bid

AVDL

Nov 19, 2025, 6:00 AM EST - 3 months ago

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

AVDL

Nov 17, 2025, 5:37 PM EST - 3 months ago

Alkermes plc (ALKS) Shareholder/Analyst Call Transcript

Nov 14, 2025, 11:37 AM EST - 3 months ago

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

AVDL

Nov 14, 2025, 9:40 AM EST - 3 months ago

H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

AVDL

Nov 14, 2025, 8:17 AM EST - 3 months ago

Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel

AVDL

Nov 14, 2025, 7:45 AM EST - 3 months ago

Alkermes Response to Avadel Announcement

Nov 14, 2025, 5:45 AM EST - 3 months ago

Avadel Receives Unsolicited Proposal from Lundbeck

AVDL

Nov 12, 2025, 12:46 PM EST - 3 months ago

Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study

Nov 12, 2025, 7:35 AM EST - 3 months ago

Alkermes' narcolepsy drug meets main goal in a mid-stage trial

Nov 12, 2025, 7:30 AM EST - 3 months ago

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

Nov 5, 2025, 9:00 AM EST - 3 months ago

FORM 8.1(a) & (b) (Opening Position Disclosure)

Nov 3, 2025, 9:58 AM EST - 4 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 28, 2025, 3:21 PM EDT - 4 months ago

Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:00 AM EDT - 4 months ago

Alkermes plc Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 3:18 PM EDT - 4 months ago

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

AVDL

Oct 22, 2025, 10:53 AM EDT - 4 months ago

Alkermes plc (ALKS) M&A Call Transcript

Oct 22, 2025, 7:11 AM EDT - 4 months ago

Alkermes to acquire Avadel for up to $2.1 billion

AVDL

Oct 22, 2025, 7:00 AM EDT - 4 months ago

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

AVDL

Oct 20, 2025, 4:00 PM EDT - 4 months ago

Alkermes to Report Third Quarter Financial Results on October 28, 2025

Sep 12, 2025, 9:00 AM EDT - 5 months ago

Alkermes Appoints Joshua Reed as Chief Financial Officer

Sep 11, 2025, 7:00 AM EDT - 5 months ago

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

Sep 8, 2025, 2:34 PM EDT - 6 months ago

Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Sep 8, 2025, 3:15 AM EDT - 6 months ago

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

Aug 25, 2025, 7:00 AM EDT - 6 months ago

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025

Jul 30, 2025, 5:08 PM EDT - 7 months ago

Alkermes: A More Than Solid Quarter

Jul 29, 2025, 2:47 PM EDT - 7 months ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:00 AM EDT - 7 months ago

Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:00 AM EDT - 7 months ago

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Jul 15, 2025, 4:00 PM EDT - 7 months ago

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Jun 2, 2025, 4:00 PM EDT - 9 months ago

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 7:00 AM EDT - 9 months ago

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

May 1, 2025, 4:31 PM EDT - 10 months ago

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible

May 1, 2025, 11:21 AM EDT - 10 months ago

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 10 months ago

Alkermes plc Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 10 months ago

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

Apr 17, 2025, 4:00 PM EDT - 11 months ago

Alkermes to Report First Quarter Financial Results on May 1, 2025

Apr 2, 2025, 4:00 PM EDT - 11 months ago

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 11 months ago

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Mar 27, 2025, 7:00 AM EDT - 11 months ago

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Feb 26, 2025, 4:00 PM EST - 1 year ago

Alkermes to Participate in Upcoming Investor Conferences

Otus Feb. 21 at 10:42 PM

$ALKS if b of a Analysis gives this a neutral rating and given their history with avadel and jazz, then this is more than likely a strong buy with a price target of 42 plus.

0 · Reply

erevnon Feb. 20 at 11:48 AM

B of A Securities maintains Alkermes $ALKS at Neutral and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

SuperGreenToday Feb. 19 at 12:13 PM

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

0 · Reply

Otus Feb. 17 at 5:08 PM

$ALKS bought several thousand more shares today.

1 · Reply

OfficialStocktwitsUser Feb. 16 at 2:07 PM

0 · Reply

Its_Only_Money_369 Feb. 13 at 11:04 PM

0 · Reply

LarryYMB Feb. 13 at 3:07 PM

$AVDL asta la vista, it didn't work fully as expected, will see you at $ALKS , cheers to you all winners, and before I forget, fk you anphony!

2 · Reply

Otus Feb. 12 at 5:07 PM

$ALKS added a few thousand shares today.

0 · Reply

jim22u Feb. 12 at 4:53 PM

$ALKS Back in for 1500 shares. Buying the fear.

0 · Reply

HoHoHoHum Feb. 12 at 1:25 PM

$ALKS Alkermes Plc completes acquisition of Avadel Pharmaceuticals plc (AVDL), accelerating entry into sleep medicine market 48 minutes agoPublished 48 minutes http://agoBriefing.com Augments Alkermes' revenue growth profile and diversifies commercial portfolio with new high potential growth product, LUMRYZ (Sodium Oxybate) for extended-release oral suspension. Expected to be accretive in 2026. Positions the combined organization to accelerate innovation and leadership in development of treatments for sleep disorders and other neurological disorders. Alkermes' financial expectations for 2026 will include certain expenses related to the transaction, including: In the first quarter of 2026, Alkermes will record transaction-related costs of $40 million. Alkermes will record approximately $180 million of LUMRYZ inventory fair value step-up, which will be expensed as cost of goods sold as the inventory is sold in 2026.Alkermes will record approximately $1.5 billion of intellectual property ….

1 · Reply

SuperGreenToday Feb. 11 at 9:03 AM

$ALKS Share Price: $34.73 Contract Selected: May 15, 2026 $35 Calls Buy Zone: $2.15 – $2.66 Target Zone: $3.83 – $4.68 Potential Upside: 68% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LarryYMB Feb. 10 at 5:48 PM

$ALKS is too boring here, lets go kill our jazzy friends!

0 · Reply

SuperGreenToday Feb. 2 at 2:28 PM

$ALKS Share Price: $33.89 Contract Selected: May 15, 2026 $35 Calls Buy Zone: $2.33 – $2.87 Target Zone: $3.98 – $4.86 Potential Upside: 61% ROI Time to Expiration: 101 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 30 at 1:56 PM

$ALKS Share Price: $34.89 Contract Selected: May 15, 2026 $35 Calls Buy Zone: $2.33 – $2.87 Target Zone: $4.15 – $5.07 Potential Upside: 68% ROI Time to Expiration: 104 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Jan. 28 at 4:38 PM

UBS⬆️ $ALKS's PT to $47 from $46/reit'd at a Buy rating. $AVDL $CNTA $TAK UBS said in its Note: ALKS stock is well-positioned to outperform in 2026, with 1) potential AVDL acquisition deal close in 1Q26, which brings in additional EBITDA growth and synergistic benefit to its Sleep franchise, and 2) two robust clinical catalysts: Lumryz and alixorexton IH trial read-outs. We believe ALKS FY26 guide for combined business could re-rate the stock: our pro-forma model (Figure 1 ALKS-AVDL Pro-forma assumptions) assumes certain level of OpEx synergies. We update our model on a pro-forma basis assuming AVDL acquisition, with a lower 4.5x EV/32E sales multiple (from ALKS prior 5.5x EV/'30E sales multiple) reflecting 1) our prior AVDL's 3.0x EV/'30E sales multiple and 2) most ALKS legacy commercial products losing exclusivity beyond 2032 with currently only a couple of early clinical-stage assets disclosed that have not been validated yet. This leads to our new PT of $47 (from $46), supported by DCF.

0 · Reply

SuperGreenToday Jan. 23 at 6:09 PM

$ALKS Share Price: $33.38 Contract Selected: May 15, 2026 $35 Calls Buy Zone: $2.25 – $2.78 Target Zone: $3.92 – $4.80 Potential Upside: 65% ROI Time to Expiration: 111 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

JFDI Jan. 21 at 5:28 PM

$ALKS

0 · Reply

Chartist0_0 Jan. 21 at 4:38 PM

$ALKS No one but me is posting on this board. And all it does is go up.

2 · Reply

OfficialStocktwitsUser Jan. 21 at 3:05 AM

$ALKS RSI: 82.92, MACD: 0.6016 Vol: 1.23, MA20: 29.20, MA50: 29.39 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Quantumup Jan. 16 at 2:10 PM

Piper Sandler reiterated $CNTA Overweight-$38 and said, There are two main catalysts for CNTA shares this quarter. $ALKS $TAK $HRMY $ESALY Piper Sandler added, First, the company expects to start Phase 3 trials testing ORX750 in NT1, NT2, and IH. Second, CNTA expects to provide add'l data from the ongoing CRYSTAL-1 Phase 2 trial. We should receive data from at least one of the three indication cohorts. Of the three indications, we believe the most underappreciated question for investors is if orexin agonists can translate meaningfully into idiopathic hypersomnia (IH), a biologically heterogeneous indication that may ultimately represent a larger market opportunity than narcolepsy type 1 (NT1) or type 2 (NT2). Despite significant unmet need, IH remains a "black box" for the field. As such, even modest efficacy signals in IH could materially shift investor perception around the breadth of ORX750's opportunity and provides asymmetric risk-reward.

0 · Reply

Quantumup Jan. 14 at 9:19 PM

TD Cowen reiterated $CNTA at a Buy rating and said, As We Await Higher Dose Data For '750, Stock Pullback Is A Good Entry Point $ALKS $TAK $ESALY $HRMY TD Cowen went on to say: https://x.com/Quantumup1/status/2011547696134307872?s=20

0 · Reply

Market Cap	5.27B
Revenue (ttm)	1.56B
Net Income (ttm)	367.07M
EPS (ttm)	N/A
PE Ratio	15.53
Forward PE	39.02
Profit Margin	23.57%
Debt to Equity Ratio	0.00

Volume	904,063
Avg Vol	1,876,712
Day's Range	N/A - N/A
Shares Out	165.12M
Stochastic %K	13%
Beta	0.49
Analysts	Strong Sell
Price Target	$43.75